These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
332 related items for PubMed ID: 10063999
21. Hemophilic patients with an inhibitor to factor VIII treated with high dose factor VIII concentrate. Results of a collaborative study for the evaluation of factor VIII inhibitor titer, recovery and half life of infused factor VIII. Sultan Y, White GC, Aronstam A, Bosser C, Brackmann HH, Brochier G, Gormsen J, Mariani G, Roberts HR, Scarabin Y. Nouv Rev Fr Hematol (1978); 1986; 28(2):85-9. PubMed ID: 3090516 [Abstract] [Full Text] [Related]
22. CD4+ T cell response to factor VIII in hemophilia A, acquired hemophilia, and healthy subjects. Reding MT, Wu H, Krampf M, Okita DK, Diethelm-Okita BM, Key NS, Conti-Fine BM. Thromb Haemost; 1999 Aug; 82(2):509-15. PubMed ID: 10605744 [Abstract] [Full Text] [Related]
23. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model. Behrmann M, Pasi J, Saint-Remy JM, Kotitschke R, Kloft M. Thromb Haemost; 2002 Aug; 88(2):221-9. PubMed ID: 12195693 [Abstract] [Full Text] [Related]
24. [Comparison of anti-human and anti-porcine factor VIII antibody titers in patients with hemophilia]. Windyga J, Rzymkiewicz L, Lopaciuk S. Acta Haematol Pol; 1996 Aug; 27(1):27-31. PubMed ID: 8629440 [Abstract] [Full Text] [Related]
27. Prevention and treatment of factor VIII inhibitors in murine hemophilia A. Qian J, Collins M, Sharpe AH, Hoyer LW. Blood; 2000 Feb 15; 95(4):1324-9. PubMed ID: 10666206 [Abstract] [Full Text] [Related]
29. Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor? Baglin T, Beacham E. Thromb Haemost; 1998 Dec 15; 80(6):1036-7. PubMed ID: 9869186 [No Abstract] [Full Text] [Related]
31. Sustained FVIII expression and phenotypic correction of hemophilia A in neonatal mice using an endothelial-targeted sleeping beauty transposon. Liu L, Mah C, Fletcher BS. Mol Ther; 2006 May 15; 13(5):1006-15. PubMed ID: 16464640 [Abstract] [Full Text] [Related]
33. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates. de Biasi R, Rocino A, Papa ML, Salerno E, Mastrullo L, De Blasi D. Thromb Haemost; 1994 May 15; 71(5):544-7. PubMed ID: 8091377 [Abstract] [Full Text] [Related]
34. Cytokine production by CD4+ T cells specific for coagulation factor VIII in healthy subjects and haemophilia A patients. Hu G, Guo D, Key NS, Conti-Fine BM. Thromb Haemost; 2007 May 15; 97(5):788-94. PubMed ID: 17479189 [Abstract] [Full Text] [Related]
35. Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A. Delignat S, Dasgupta S, André S, Navarrete AM, Kaveri SV, Bayry J, André MH, Chtourou S, Tellier Z, Lacroix-Desmazes S. Haematologica; 2007 Oct 15; 92(10):1423-6. PubMed ID: 18024377 [Abstract] [Full Text] [Related]
39. A Treg-Selective IL-2 Mutein Prevents the Formation of Factor VIII Inhibitors in Hemophilia Mice Treated With Factor VIII Gene Therapy. Chen AC, Cai X, Li C, Khoryati L, Gavin MA, Miao CH. Front Immunol; 2020 Oct 15; 11():638. PubMed ID: 32411127 [Abstract] [Full Text] [Related]